唑来膦酸化疗对非小细胞肺癌骨转移疗效及白细胞介素-6肿瘤坏死因子-α的影响
参考文献2
-
1董梅,陈学鹏,冯奉仪.双膦酸盐治疗恶性肿瘤骨转移的研究进展[J].中华肿瘤杂志,2007,29(11):801-803. 被引量：8
-
2Kubota A,Hasegawa K,Suguro T,et al.Tumor necrosis factor-αl phapromotes the expression of osteoprotegerin in rheumatoidsyn ovial fibroblasts.Rheumatol,2004,31(3):426-435.
二级参考文献21
-
1Bukowski JF, Dascher CC, Das H. Alternative bisphosphonate targets and mechanisms of action. Biochem Biophys Res Commun, 2005, 328:746-750.
-
2Ferretti G, Fabi A, Carlini P, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory eytokines in metastatic breast cancer patients. Oncology, 2005, 69:35-43.
-
3Clezardin P, Ebetino FH, Foumier PG. Bisphosphonates and cancerinduced bone disease: beyond their antireserptive activity. Cancer Res, 2005, 65:4971-4974.
-
4Pavlakis N, Stockier M. Bisphosphonates for breast cancer. Cochrane Database Svst Rew. 2005. CD003474.
-
5Tripathy D, Lichinitzer M, Lazarev A, et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol, 2004, 15:743-750.
-
6Body JJ, Diel IJ, Bell R, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain, 2004, 111:306-312.
-
7Heidenreich A, Ohlmann C, Body JJ. Ibandronate in metastatic bone pain. Semin Oncol, 2004, 31:67-72.
-
8Pecherstorfer M. Efficacy and safety of ibandronate in the treatment of neoplastic bone disease. Expert Opin Pharmacother, 2004, 5: 2341-2350.
-
9Smith MR. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rew, 2005, 3:19-25.
-
10Saad F, Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int, 2005, 96:964-969.
共引文献7
-
1修海峰.纤维支气管镜刷片细胞学检查的临床意义[J].淮海医药,2008,26(3):232-232.
-
2胡莉钧,李毅,聂斌.放疗联合唑来膦酸姑息性治疗骨转移癌86例疗效分析[J].中国医药指南,2011,9(16):99-100. 被引量：5
-
3何馥倩,廖再波,黄晓丽.以右踝局部炎症反应为首发表现的肺癌孤立性骨转移一例[J].华西医学,2013,28(4):526-527.
-
4李鹏飞,贾楠,沈亚欣,杨建博,靳宪辉,丁文元,张为.不同浓度伊班膦酸钠对体外培养破骨细胞活性和骨吸收作用的影响[J].颈腰痛杂志,2013,34(5):372-376. 被引量：2
-
5谢晓娟,佟仲生.乳腺癌骨转移的内科治疗[J].国际肿瘤学杂志,2015,42(12):920-923. 被引量：3
-
6杨辉,胡庆涛,段寄辉.早期应用双膦酸盐治疗乳腺癌骨转移的临床价值探析[J].当代医学,2016,22(12):8-9. 被引量：3
-
7冯晨,李中梨,张文学.双膦酸盐因卡膦酸二钠的临床研究与应用[J].肿瘤综合治疗电子杂志,2019,5(2):46-49. 被引量：5
-
1赵耀,李敬朝,王传庆,战英,侯代伦.肺结核并胸腰椎及骶髂结核误诊为肺癌骨转移1例报告[J].中国脊柱脊髓杂志,2014,24(2):190-192. 被引量：1
-
2付西峰,赵浩亮,鲍民生.雷公藤对大鼠急性坏死性胰腺炎时急性肺损伤的治疗以及对肿瘤坏死因子-α的影响[J].中国药物与临床,2010,10(3):286-287. 被引量：3
-
3席海林,邓学军,赵咏梅.辛伐他汀对慢性心力衰竭患者脑钠肽及肿瘤坏死因子-α的影响[J].临床心血管病杂志,2008,24(6):430-432. 被引量：3
-
4吴静,徐亮,杜华,王运茹.氯吡格雷对急性冠脉综合征患者PCI术后超敏C反应蛋白和肿瘤坏死因子-α的影响[J].疑难病杂志,2012,11(8):575-577. 被引量：9
-
5庞晓,梁君惠,刘红阳,席燕.卡维地洛对充血性心力衰竭患者一氧化氮、内皮素-1及肿瘤坏死因子-α的影响[J].临床心血管病杂志,2005,21(10):582-583. 被引量：8
-
6赵新国.不同剂量阿托伐他汀对冠心病患者血脂水平、白介素-6及肿瘤坏死因子-α的影响[J].海军总医院学报,2011,24(4):202-204. 被引量：6
-
7杨素霞,郭岩岩,杨秀真,赵清,陈宝平.百令胶囊对糖尿病肾病肿瘤坏死因子-α的影响[J].中国药师,2010,13(11):1638-1639.
-
8朱媛媛,王美记.阿托伐他汀对高血压患者hs-CRP和TNF-α的影响[J].北方药学,2015,12(4):131-131. 被引量：1
-
9袁国会,杨钧国,于凌云,任法鑫,杜戎,桂乐.胺碘酮对缺血性心肌病心力衰竭患者肿瘤坏死因子-α的影响[J].中国综合临床,2005,21(3):205-207.
-
10刘军利.辛伐他汀对慢性心力衰竭患者心功能及肿瘤坏死因子-α的影响[J].中国医药导报,2008,5(25):67-67. 被引量：3
